Monica Gray

Monica has an undergraduate degree in Accounting and an MBA she earned - with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.
Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Bounces off Lows

Immune Design Corp (NASDAQ:IMDZ)

Shares of Immune Design Corp (NASDAQ:IMDZ) gained 12.2% ahead of their much-awaited financial results for the third quarter, ended September 30, 2017. The clinical stage immunotherapy company will release the results on November 1, 2017, after the close of the U.S. markets.

Immune Design Corp (NASDAQ:IMDZ)

Earnings Expectations

Investor confidence in the stock has taken a hit this month as seen by the stock shedding more than 50% in its market value. The stock has come under pressure following the pricing of an underwritten public offering of 19.5 million shares at a price of $4.10 a share. Investors pushed the stock lower after the company offered the shares at a discount to the market price.

Last quarter, the immunotherapy company reported a positive earnings surprise of 16.92% outpacing the consensus estimates of average earnings beat of 12.94%. A similar performance with Q3 financial results could result in the stock bouncing back from current trading levels.

Increased implied volatility on Immune Design Corp (NASDAQ:IMDZ) November options is already fuelling suggestions of a potential big move in either direction. Analysts at Zack’s research currently rate the stock as a ‘hold’.

Immune Design Pipeline

Progress on the company’s pipeline candidates should have an impact on the stock’s direction of trade going forward. The company’s lead candidate drugs are CMB305 for the treatment of solid tumor and G100 for the treatment of merkel cell carcinoma.

Immune Design is evaluating CMB305 both as a monotherapy and in combination with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Tecentriq. G100 is being developed on the GLAAS platform in collaboration with Merck for the treatment of patients with non-Hodgkin’s lymphoma (NHL).

The European Medicine Agency has granted G100 Orphan Drug Designation for the treatment of NHL. The designation is expected to accelerate its development while also guaranteeing market exclusivity for up to 10 years.

Immune Design Corp (NASDAQ:IMDZ) has the financial power to accelerate the development of the two candidate drugs given the pricing of the $80 million public offering.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Aviragen Therapeutics Inc (NASDAQ:AVIR) Shares Drop on Merger Announcment

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Shares of Aviragen Therapeutics Inc (NASDAQ:AVIR) are having their most volatile day in months after the biotechnology company announced that they were merging with Vaxart, Inc., a privately-held, clinical-stage company focused on developing oral recombinant vaccines. The merger will result in a combined company, Vaxart, Inc., focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Wouter Latour, M.D., Chief Executive Officer of Vaxart stated “This transaction gives us the opportunity to build on the positive Phase 2 challenge study results we announced recently for our influenza oral tablet vaccine, as well as the excellent results we obtained in the safety and immunogenicity studies with our norovirus vaccine.  Additionally, it will provide us access to Aviragen’s antiviral assets, including their BTA074 Phase 2 program for the treatment of condyloma caused by HPV, which is on track to complete enrollment this quarter and to report top-line safety and efficacy data in the second quarter of 2018.”

Deal Details

The exchange ratio was determined by assigning $60 million in value to Aviragen Therapeutics Inc (NASDAQ:AVIR) for its financial and clinical assets and $90 million in value for Vaxart’s assets. On a pro forma basis, after giving effect to the number of shares of Aviragen common stock issued in the merger, Vaxart’s securityholders will own approximately 60% of the combined company and Aviragen Therapeutics Inc (NASDAQ:AVIR) shareholders will own approximately 40% of the combined company.

AVIR Stock Review

AVIR shares ended Friday at $0.83 then gapped up this morning to open at $0.96 on the merger news. The shares went on to hit an inter-day high of $1.08 before sellers came in a pushed the price down to a low of $0.67. Currently shares are trading around the $0.70 handle.

AVIR shares have done well since they hit a 52-week low early this past summer at $0.43. For the month they are up over 27% and up for the quarter by a whopping 50%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVIR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Micronet Enertec Technologies Inc (NASDAQ:MICT)

Micronet Enertec Technologies Inc (NASDAQ:MICT) Shares Have Strong Rebound

Micronet Enertec Technologies Inc (NASDAQ:MICT)

Micronet Enertec Technologies Inc (NASDAQ:MICT) shares are off their inter-day highs but are still up over 21% after the company announced that its wholly owned subsidiary received a $3.1 million order. The defense technology company has a $5.5 million market capitalization and observers believe this order might significantly strengthen the company’s earnings. In the last four months, Micronet has booked over $9,000,000 in orders received for their ELD solutions.

Micronet Enertec Technologies Inc (NASDAQ:MICT)

The $3.1 million purchase order is for the company’s recently released SmartHub-TREQr5 product. The SmartHub-TREQr5 is an Android on-board computer optimized for Internet of Things (IOT) and fleet management applications. SmartHub-TREQr5 improves efficiencies and safety for trucking and other fleet management operations.

David Lucatz, Chief Executive Officer of Micronet Enertec Technologies stated in a press release, “We believe that $9,000,000 in total orders in just four months clearly indicates the market’s growing demand for electronic logging device (ELD) products and, more importantly, Micronet’s power to design and deliver MRM technologies that optimally serve customers’ needs. We are pleased with the pace at which Micronet is closing on new sales and we look forward to shipping on this purchase order.”

In July of 2016, Micronet Enertec Technologies Inc (NASDAQ:MICT) shares briefly traded above the psychologically-important $2.50 level. Since then the shares have been sliding and permanently broke below the $1 per share threshold early this past summer. There have been several attempts for the stock to break above $1, but every rally met with strong selling.

Year-to-date MICT shares are down almost 50% and are down almost 25% over the past month. The company’s fundamentals match its stock performance. In 2013, Micronet Enertec Technologies Inc (NASDAQ:MICT) hit its high sales point of $35.6 million. By 2016, the company reported sales of just $22.7 million. Likewise, per share earnings have been on a similar slide. In 2012 Micronet posted a per share profit of $1.67. The next year the company posted a loss and the per share losses have been expanding ever since. For 2016 the per share loss was (-$0.97).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MICT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX) Bounce back Gathers Momentum

Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics Inc. (NASDAQ:RPRX) rebound from this year’s lows of $0.26 a share continued in Friday’s trading session, as its shares gained 3.11% to end the week at $0.5336. However, the stock is still down for year-to-date after losing more than 50% in market value since January.

Repros Therapeutics Inc. (NASDAQ:RPRX)

FDA Clinical Hold Debacle

Investor confidence in Repros Therapeutics Inc. (NASDAQ:RPRX) took a hit in June after the U.S. Food and Drug Administration (FDA) instituted a clinical hold on the company’s Proellex program for the treatment of uterine fibroids. According to the agency, Repros Therapeutics Inc. (NASDAQ:RPRX) will have to conduct a much larger clinical study if the FDA is to lift the partial clinical hold. A point of concern to investors is that the additional requirements could end up being expensive and time-consuming.

This is not the first time that the biopharmaceutical company has found itself at odds with the FDA with regards to the development of Proellex. In 2009, the FDA placed the program under clinical hold, but later allowed it to continue under partial clinical hold with low oral dosage.

Repros Therapeutics Inc. (NASDAQ:RPRX) is also evaluating Proellex in its Phase IIb study for uterine fibroids by vaginal delivery. The company says it plans to increase its focus on this study given that it does not have clinical hold issues.

“Clinical work done to date suggests that vaginal delivery of telapristone acetate has the potential to yield good efficacy with significantly lower systemic blood levels. Furthermore, we intend to leverage drug delivery technology that could offer to dose less frequently than once per day,” said CEO, Larry Dilaha.

Q2 Net Loss

The Texas-based biopharmaceutical company reported a net loss of (-$2.2) million or (-$0.08) a share for the three months ended June 30, 2017, compared to a net loss of (-$4.3) million a year ago. The decline was primarily due to a decrease in clinical development expenses related to Proellex and enclomiphene product candidates.

Repros Therapeutics Inc. (NASDAQ:RPRX)’s net loss for the first six months of the year stood at (-$8.1) million or (-$0.30) a share, compared to a net loss of (-$9.1) million for the corresponding period last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RPRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) Drops

Atossa Genetics Inc. (NASDAQ:ATOS)

Atossa Genetics Inc. (NASDAQ:ATOS) felt the wrath of Wall Street after announcing the pricing of a $5.1 million public offering of common stock. Shares of the clinical stage pharmaceutical company fell 46.9%, to end Thursday’s trading session at $0.45 a share.

Atossa Genetics Inc. (NASDAQ:ATOS)

Public Offering Reaction

The company has priced 11.5 million shares of common stock at a public offering price of $0.44 a share. Atossa Genetics Inc. (NASDAQ:ATOS) has also granted underwriters an overallotment option for the purchase of 1 million additional shares of common stock. Gross proceeds before deduction of underwriting discounts, commissions, and other estimated offering costs should be about $5.1 million.

Atossa Genetics Inc. (NASDAQ:ATOS) plans to use net proceeds from the offering for general corporate purposes. The offering should close on or about October 30, 2017.

The $5.1 million public offering appears to have spooked investors as the stock dropped from $1.50 a share to $0.45. Following the slump, the stock is now down by more than 40% for the year.

Oral Endoxifen Trials

The pricing of the public offering comes just days after the clinical stage pharmaceutical company announced preliminary results from its Phase 1 study of Oral Endoxifen. The company is investigating the drug for the treatment of recurrent breast cancer.

Trial results indicate that Endoxifen met all its objectives with no clinically significant safety signals or adverse events reported. Oral Endoxifen was also well tolerated at each dose levels. According to Atossa Genetics Inc. (NASDAQ:ATOS), the study results demonstrate the sustainability of oral Endoxifen for further clinical development.

“Based on these positive preliminary results, we are advancing our oral Endoxifen into Phase 2 studies,” commented Dr. Steven C. Quay, CEO, and President. “We expect our initial Phase 2 study will be in women who are refractory to Tamoxifen and we expect to begin that study in the first quarter of 2018,” continued Dr. Quay.

Estimates indicate that about 250,000 women will be diagnosed with breast cancer in the U.S this year with 40,000 expected to die. Breast cancer is the second leading cause of cancer death in the US. Atossa Genetics Inc. (NASDAQ:ATOS) estimates the potential market for its oral and tropical formulation of Endoxifen if approved at over $1 billion.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ATOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) Continues Uptrend

Sierra Oncology Inc. (NASDAQ:SRRA)

Sierra Oncology Inc. (NASDAQ:SRRA) traded higher after announcing the appointment of Dr. Andrew Allen to its Board of Directors. The stock was up by 12.6% in Wednesday’s trading session to end the day at $2.14 a share.

Sierra Oncology Inc. (NASDAQ:SRRA)

Wednesday’s rally saw the stock break a key resistance level at $1.90, affirming a bullish run that began in June. The stock is now up by more than 30% for the year as it continues to trade in a strong uptrend marked by a new 52-week high of $2.20 a share.

The appointment of Dr. Allen comes at a time when the clinical stage drug development company is advancing next-generation DNA Damage Response therapies for the treatment of patients with cancer. He joins the company with vast experience, having served as the Chief Executive of Gristone Oncology, and as Chief Medical Officer at Pharmion Corporation.

“I’ve been highly encouraged by the sophisticated approach Sierra is taking to developing SRA737, leveraging the rich biology of Chk1 synthetic lethality to incorporate prospective genomic profiling strategies to enhance patient selection in their trials and potentially improve their prospects for positive outcomes. I look forward to working closely with this outstanding team,” said Dr. Allen.

SRA737 Development

Sierra Oncology Inc. (NASDAQ:SRRA) will report preclinical data supporting the development of SRA737 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer on October 26-30, 2017. The candidate drug is currently being investigated in two Phase 1 clinical trials in patients with advanced cancer.

The Chk1 inhibitor, SRA737 has been granted a selection patent by the U.S Patent and Trademark Office, which extends coverage until 2033. A similar European patent was issued in February. According to Sierra Oncology, the intellectual property establishes a solid foundation for the potential future commercialization of the promising candidate drug

“We anticipate generating additional intellectual property claims as we advance our DDR-focused research activities and our innovative genetics-driven clinical programs,” said CEO Nick Glover.

Q2 Financial Results

Separately, Sierra Oncology Inc. (NASDAQ:SRRA) reported a net loss of (-$10.3) million for the three months ended June 30, 2017, down from a net loss of (-$12.9) million reported a year ago. Cash and cash equivalent as of the end of the quarter stood at $125 million compared to $109 million as of December 31, 2016. According to the clinical stage company, the existing cash is sufficient to fund operations through mid-2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Quotient Ltd (NASDAQ:QTNT) Reports 99.8% Blood Grouping Concordance

Quotient Ltd (NASDAQ:QTNT)

Quotient Ltd (NASDAQ:QTNT) shares gained 11.9% after the diagnostics company reported positive concordance data from MosaiQ Verification and validation studies in blood grouping. According to the Chief Executive Officer, Paul Cowan, 99.8% blood grouping concordance demonstrates the robustness of MosaiQ as a diagnostics platform.

Quotient Ltd (NASDAQ:QTNT)

MosaiQ Platform Development

The positive study results mark an important milestone in the development of the highly informative and disruptive testing platform for transfusion diagnostics. Quotient Limited has also demonstrated feasibility of the platform with respect to detection of nucleic acids.

Over the next 12 months, Quotient Ltd (NASDAQ:QTNT) plans to carry out European field trials and then file for European regulatory approval. MosaiQ European commercialization has already began with the company expecting tender offers in FY2018.

Quotient Ltd (NASDAQ:QTNT) stock gapped higher on the news – touching highs of $5.52 a share before it dropped to end Wednesday’s trading session at $5.19.

Private Placement

In addition, Quotient Ltd (NASDAQ:QTNT) has entered into agreements with certain shareholders for the issuance of 7.9 million shares priced at $4.64 a share. The company has also issued 550,000 pre-funded warrants at $4.75 and exercisable for up to 550,000 ordinary shares, priced at $0.01 per ordinary share.

Quotient Ltd (NASDAQ:QTNT) expects aggregate proceeds of $40 million from the private placement. The company expects an additional $49 million on the exercise of 8.4 million warrants priced at $0.125 a warrant. Net proceeds from the offering are to be used to fund the ongoing development and commercial scale-up of MosaiQ and for working capital among other general corporate purposes. The offering should close on or about October 26, 2017.

“I am also pleased that we have strengthened our balance sheet through our recently announced private placement, which was led by a small group of existing shareholders, with participation by directors and management. This financing is an added vote of confidence for what we have achieved to date and what we have the potential to achieve in the future,” said Mr. Cowan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $QTNT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX)’s VK2809 Succeeds in Trial

Viking Therapeutics Inc. (NASDAQ:VKTX)

Viking Therapeutics Inc. (NASDAQ:VKTX) fell 5.36% after announcing positive results from an eight-week study of VK2809 as a novel treatment for a wide range of lipid disorders. Study results demonstrate lipid-lowering effects of the small molecule thyroid receptor, as well as anti-fibrotic benefits.

Viking Therapeutics Inc. (NASDAQ:VKTX)

VK2809 vs. Lipid Disorders

Treatment with VK2809 shows statistically significant reductions in liver triglycerides, liver cholesterol, and total lipids in treated animals, relative to vehicle controls. The trials also showed significant changes in expression of key genes associated with non-alcoholic Steatohepatitis development and progression.

“The observed changes in gene expression are exciting, as they corroborate the histologic improvements and suggest potential benefits of insulin sensitivity and metabolic control. VK2809’s therapeutic and safety profile continue to suggest a promising potential role in settings such as NASH and hyperlipidemia,” said CEO, Brian Lian.

Viking Therapeutics Inc. (NASDAQ:VKTX) is trading in an uptrend despite the 5% drop. The stock is up by more than 100% for the year and outperforming the overall industry. Renewed investor interest follows positive clinical trials of the company’s lead program VK2809 and VK0214.

According to Viking Therapeutics Inc. (NASDAQ:VKTX), VK2809 was well tolerated with no significant changes to liver functions it to test subjects relative to controls. VK2809 is a small molecule thyroid receptor that promises therapeutic potential in a range of lipid disorders.

Clinical data has already demonstrated that treatment with VK2809 could lead to a significant reduction in plasma triglycerides as well as LDL Cholesterol in subjects with mild hypercholesterolemia. Viking Therapeutics is currently evaluating it in a randomized, double-blind, placebo-controlled parallels group Phase 2 study.

VK0214 Development

In addition to VK2809, Viking Therapeutics Inc. (NASDAQ:VKTX) is also evaluating VK0214 on the treatment of X-linked adrenoleukodystrophy. The U.S. Food and Drug Administration has already granted the thyroid receptor beta Orphan Drug status.

Study results from a 25-week proof-of-concept study showed VK0214 led to statistically significant reductions in Plasma levels of very long chain fatty acids in treated animals. The therapy also demonstrated reductions in long chain fatty acids in tissues such as in the liver, brain, and spinal cord.

“The impressive effects on plasma VLCFAs strengthen our belief that activation of the thyroid beta receptor can lead to improved lipid processing. The reduction in tissue VLCFAs is particularly exciting, as it suggests a potential direct benefit on tissue-related toxicities,” said Brian Lian, Ph.D., chief executive officer of Viking.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VKTX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Pulmatrix Inc. (NASDAQ:PULM)

Pulmatrix Inc. (NASDAQ:PULM)’s PUR1900 Awarded Designation

Pulmatrix Inc. (NASDAQ:PULM)

Shares of Pulmatrix Inc. (NASDAQ:PULM) fell 4.86% in Tuesday’s trading session to end the day at $1.76 a share. The sell-off comes just days after the U.S. Food and Drug Administration (FDA) designated the clinical stage biopharmaceutical company’s candidate drug, Pulmazole (PUR1900), as a Qualified Infectious Disease Product (QIDP).

Pulmatrix Inc. (NASDAQ:PULM)

FDA Designation

The designation is designed to speed up the development of novel drugs that have the potential to address important pathogens. Pulmatrix stands to enjoy up to 5 years of market exclusivity should the drug succeed in clinical trials and gain regulatory approval.

The candidate drug has already achieved orphan drug designation for the treatment of fungal infections in the airways of patients with cystic fibrosis. The QIDP designation further expands PUR 1900 status to include Asthma patients

“This second QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to severe asthma patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review and significantly expands the potential population we can treat with our Pulmazole product.

Patent Protection Milestone

In addition to FDA designation milestones, Pulmatrix Inc. (NASDAQ:PULM) has received two important patents from the United States Patent and Trademark Office (USPTO). One of the patents expands the potential of the company’s technology for delivering drugs directly to the lungs.

The company has developed a dry powder that it claims can fly easily through the airways and deliver a wide range of types of drugs. The technology is designed to increase the efficiency of drug delivery while also reducing the side effects associated with existing approaches.

The second patent expands the patent protection of Pulmatrix Inc. (NASDAQ:PULM) candidate drug PURO200 for the treatment of chronic obstructive pulmonary disease. The new patent broadens the intellectual property protection so that it is no longer limited to specific characteristics and performance criteria.

“The new PUR0200 patent will make it more difficult for potential competitors to develop similar products or to work around our product candidate,” explained Robert W. Clarke, Ph.D., Chief Executive Officer for Pulmatrix. “The new claims also will make it possible for us to add in a second therapeutic to create a combination product.”

Pulmatrix Inc. (NASDAQ:PULM) is currently developing PUR0200 in Europe and the United States, following regulatory pathways that offer quickest approvals.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PULM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

OpGen Inc. (NASDAQ:OPGN)

OpGen Inc. (NASDAQ:OPGN) Awarded $860,000 CDC Contract

OpGen Inc. (NASDAQ:OPGN)

Shares of OpGen Inc.(NASDAQ:OPGN) fell 1.4% after the Center for Disease Control and Prevention awarded the company a contract for the development of clinical support tools for antimicrobial stewardship and infection control. The agency has since granted the company $860,000 for the development of a cloud-based mobile software which is to be used in low and middle-income countries.

OpGen Inc. (NASDAQ:OPGN)

CDC Contract Award

OpGen Inc. (NASDAQ:OPGN) is to work with Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc. to bring the solution to fruition. Teqqa is to provide a cloud and mobile based software platform to support antimicrobial stewardship.

The platform is to be used to identify patients that require infection control precautions and assist in the implementations of the necessary precautions. The software will be translated into Spanish to support WHONET data integration.

“OpGen looks forward to working with the CDC to help address this urgent global need,” stated Evan Jones, CEO of OpGen. “Improving antimicrobial stewardship worldwide has been identified by the CDC, the World Health Organization (WHO) and governments worldwide as a core activity in the fight to contain and manage infections from multidrug-resistant pathogens.”

OpGen Inc. (NASDAQ:OPGN) is also developing the Acuitas AMR Gene Panel u5.47, a PCR test designed to detect antibiotic resistance genes. The test can detect up to five bacterial pathogens in clinical isolate and urine specimens. It can also be used to detect up to 47 antimicrobial resistance genes.

According to OpGen’s senior vice president of research and development, Dr. Terry Walker, antimicrobial drug resistance is an urgent global health concern.

“Our data show that the Acuitas AMR Gene Panel accurately detects and quantitates key complicated urinary tract infection pathogens. We are encouraged by the development data for Acuitas Lighthouse Knowledgebase prediction algorithms currently in development,” said Dr. Walker.

OPGN Stock Performance

The CDC award did little to strengthen investor confidence in the precision medicine company. The stock has underperformed the overall industry, having shed more than 70% in market value since the start of the year.

OpGen Inc. (NASDAQ:OPGN) is currently trading in a downtrend as investors sentiments on the street continue to drop. However, the stock is currently rated as a ‘strong buy’ by two analyst firms according to data compiled by Zacks Investment Research.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPGN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.